MX2021002208A - Regimenes de dosificacion de la proteina de fusion de fc y dominio extracelular del cd80. - Google Patents

Regimenes de dosificacion de la proteina de fusion de fc y dominio extracelular del cd80.

Info

Publication number
MX2021002208A
MX2021002208A MX2021002208A MX2021002208A MX2021002208A MX 2021002208 A MX2021002208 A MX 2021002208A MX 2021002208 A MX2021002208 A MX 2021002208A MX 2021002208 A MX2021002208 A MX 2021002208A MX 2021002208 A MX2021002208 A MX 2021002208A
Authority
MX
Mexico
Prior art keywords
extracellular domain
fusion protein
dosing regimens
protein dosing
domain
Prior art date
Application number
MX2021002208A
Other languages
English (en)
Inventor
Kristen Pierce
Hong Xiang
Susannah D Barbee
Sandeep P Inamdar
Original Assignee
Five Prime Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc filed Critical Five Prime Therapeutics Inc
Publication of MX2021002208A publication Critical patent/MX2021002208A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción proporciona métodos para administrarle proteínas de fusión que comprenden el dominio extracelular del grupo de diferenciación 80 (CD80) humano y el dominio de fragmento cristalizable (Fc) de la inmunoglobulina G 1 (IgG1) humana a un sujeto que lo necesite, por ejemplo, un paciente con cáncer.
MX2021002208A 2018-08-29 2019-08-28 Regimenes de dosificacion de la proteina de fusion de fc y dominio extracelular del cd80. MX2021002208A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862724443P 2018-08-29 2018-08-29
US201962818462P 2019-03-14 2019-03-14
PCT/US2019/048560 WO2020047087A1 (en) 2018-08-29 2019-08-28 Cd80 extracellular domain fc fusion protein dosing regimens

Publications (1)

Publication Number Publication Date
MX2021002208A true MX2021002208A (es) 2021-05-14

Family

ID=68063025

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002208A MX2021002208A (es) 2018-08-29 2019-08-28 Regimenes de dosificacion de la proteina de fusion de fc y dominio extracelular del cd80.

Country Status (12)

Country Link
US (1) US20210340214A1 (es)
EP (1) EP3843767A1 (es)
JP (1) JP2021535083A (es)
KR (1) KR20210049814A (es)
CN (1) CN112543642A (es)
AU (1) AU2019333059A1 (es)
BR (1) BR112021003758A2 (es)
CA (1) CA3108064A1 (es)
IL (1) IL281003A (es)
MX (1) MX2021002208A (es)
SG (1) SG11202100642UA (es)
WO (1) WO2020047087A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201891106A1 (ru) 2015-11-02 2018-12-28 Файв Прайм Терапьютикс, Инк. Полипептиды внеклеточного домена cd80 и их применение в лечении рака
US11789010B2 (en) 2017-04-28 2023-10-17 Five Prime Therapeutics, Inc. Methods of treatment with CD80 extracellular domain polypeptides
EP4054721A1 (en) * 2019-11-04 2022-09-14 Five Prime Therapeutics, Inc. Cd80 extracellular domain fc fusion protein dosing regimens
US20240228578A1 (en) * 2020-02-26 2024-07-11 Five Prime Therapeutics, Inc. Cd80 extracellular domain fc fusion protein therapy
CA3185332A1 (en) 2020-06-03 2021-12-09 Boehringer Ingelheim International Gmbh Recombinant rhabdovirus encoding for a cd80 extracellular domain fc-fusion protein

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE469888T1 (de) 2003-05-22 2010-06-15 Abbott Lab Indazol-, benzisoxazol- und benzisothiazol- kinaseinhibitoren
WO2005108432A2 (en) * 2004-03-30 2005-11-17 Indiana University Research & Technology Corporation Cd80 (b7-1) binding peptides and uses thereof
NZ565511A (en) * 2005-07-22 2011-03-31 Five Prime Therapeutics Inc Compositions and methods of treating disease with FGFR fusion proteins
AU2006294511B2 (en) * 2005-09-28 2011-11-17 Zymogenetics, Inc IL-17A and IL-17F antagonists and methods of using the same
KR101383476B1 (ko) * 2007-11-01 2014-04-11 아스테라스 세이야쿠 가부시키가이샤 면역억제 폴리펩티드 및 핵산
CN102203125A (zh) * 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂及其使用方法
US11319359B2 (en) * 2015-04-17 2022-05-03 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
EA201891106A1 (ru) * 2015-11-02 2018-12-28 Файв Прайм Терапьютикс, Инк. Полипептиды внеклеточного домена cd80 и их применение в лечении рака
EP3380523A1 (en) * 2015-11-23 2018-10-03 Five Prime Therapeutics, Inc. Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
CN110352245A (zh) * 2016-10-20 2019-10-18 高山免疫科学股份有限公司 可分泌变体免疫调节蛋白和工程化细胞疗法
US11789010B2 (en) * 2017-04-28 2023-10-17 Five Prime Therapeutics, Inc. Methods of treatment with CD80 extracellular domain polypeptides

Also Published As

Publication number Publication date
EP3843767A1 (en) 2021-07-07
JP2021535083A (ja) 2021-12-16
CA3108064A1 (en) 2020-03-05
SG11202100642UA (en) 2021-03-30
BR112021003758A2 (pt) 2021-05-25
IL281003A (en) 2021-04-29
WO2020047087A1 (en) 2020-03-05
CN112543642A (zh) 2021-03-23
AU2019333059A1 (en) 2021-03-18
US20210340214A1 (en) 2021-11-04
KR20210049814A (ko) 2021-05-06

Similar Documents

Publication Publication Date Title
MX2021002208A (es) Regimenes de dosificacion de la proteina de fusion de fc y dominio extracelular del cd80.
PH12021550802A1 (en) Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
PH12017502025A1 (en) Fusion proteins
MY180831A (en) Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
MX2020006715A (es) Anticuerpos especificos del heterodimero de cd3-delta/epsilon.
MX2021000083A (es) Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunes.
CA3010621A1 (en) Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
MX2021010061A (es) Proteínas de fusión fc con dominio extracelular de cd80 para tratar tumores negativos para pd-l1.
SG10201804945WA (en) Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
MX2021006017A (es) Polipeptidos de folistatina y sus usos.
AU2015255979B2 (en) Using B-cell-targeting antigen IgG fusion as tolerogenic protein therapy for treating adverse immune responses
SG10201805411YA (en) Chimeric antigen receptors
MX2021010840A (es) Composiciones de anhidrasa carbónica 2 (ca2) humana y métodos de regulación ajustable.
EP4249064A3 (en) Novel fusion protein specific for cd137 and pd-l1
MX2021005565A (es) Anticuerpos monoclonales antagonistas contra cumulo de diferenciacion 40 (cd40) y sus usos.
WO2020136145A3 (en) Leucocyte immunoglobulin-like receptor 2 neutralizing antibodies
MX2022009100A (es) Proteinas de fusion fc heterodimericas il15/il15r alfa para el tratamiento de cancer.
WO2020132658A3 (en) Tubulysins and protein-tubulysin conjugates
MX2020008730A (es) Regímenes de dosificación de anticuerpo b7-h4.
WO2021181233A3 (en) Cd80-fc fusion protein and uses thereof
MX2022001380A (es) Anticuerpos de fcrn y metodos de uso de los mismos.
BR112019020386A2 (pt) vacinas de peptídeos de pd-1 humana e usos das mesmas
MX2022004058A (es) Kir3dl3 es un receptor inhibidor del sistema inmunitario y usos del mismo.
MX2022001065A (es) Anticuerpo anti-bcma, fragmento de union al antigeno y uso medico del mismo.
JOP20190259A1 (ar) بروتينات ربط مولد ضد مضادة لـ jagged1